LBP Antikörper

Produktnummer ABIN343177

Produktdetails anti-LBP Antikörper

Target: LBP (Lipopolysaccharide Binding Protein (LBP))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser LBP Antikörper ist unkonjugiert

Applikation: ELISA, Functional Studies (Func)

Aufreinigung: Protein G purified

Immunogen: LBP knock out mouse immunized with immunoaffinity purified recombinant human LBP

Klon: BiG 412

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: inhibition of LPS binding to membrane bound CD14, inhibition titre 1:1000. Binding titre at human LBP- ELISA: 1:50.000, cross reacting with bovine LBP.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Konzentration: 2.0 mg/ml (determined by mouse IgG-ELISA) before lyophilization

Buffer: with NaN3

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Referenzen für anti-LBP Antikörper (ABIN343177)

Muansson, Kjaell, Pellett, Nagy, Welch, Baeckhed, Frisan, Richter-Dahlfors: "Role of the lipopolysaccharide-CD14 complex for the activity of hemolysin from uropathogenic Escherichia coli." in: Infection and immunity, Vol. 75, Issue 2, pp. 997-1004, (2007) (PubMed).

Kato, Ogasawara, Homma, Saito, Matsumoto: "Lipopolysaccharide-binding protein critically regulates lipopolysaccharide-induced IFN-beta signaling pathway in human monocytes." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 172, Issue 10, pp. 6185-94, (2004) (PubMed).

Berner, Fürll, Stelter, Dröse, Müller, Schütt: "Elevated levels of lipopolysaccharide-binding protein and soluble CD14 in plasma in neonatal early-onset sepsis." in: Clinical and diagnostic laboratory immunology, Vol. 9, Issue 2, pp. 440-5, (2002) (PubMed).

Vidal, Labéta, Schiffrin, Donnet-Hughes: "Soluble CD14 in human breast milk and its role in innate immune responses." in: Acta odontologica Scandinavica, Vol. 59, Issue 5, pp. 330-4, (2001) (PubMed).

Details zu LBP

Target: LBP (Lipopolysaccharide Binding Protein (LBP))

Andere Bezeichnung: Lipopolysaccharide (LPS)-Binding Protein (LBP) (LBP Produkte)

Synonyme: BPIFD2 antikoerper, Bpifd2 antikoerper, Ly88 antikoerper, LPSBP antikoerper, LBP antikoerper, lipopolysaccharide binding protein antikoerper, lipopolysaccharide-binding protein antikoerper, LBP antikoerper, Lbp antikoerper, LOC100472839 antikoerper

Hintergrund: LPS binding protein (LBP) is an approximately 60 kDa acute phase protein that is produced by hepatocytes. This protein strongly binds to LPS and has been shown to play an important role in the handling of LPS by the host. A number of functions of LBP have been reported. First, LBP transfers LPS to the LPS receptor CD14 on mononuclear phagocytes, leading to a 100-1,000-fold increased sensitivity of the cells to LPS. Furthermore, LBP can enhance the response of CD14 negative cells by acceleration of LPS binding to soluble CD14, a complex that stimulates these cells. Next, LBP transfers LPS into High Density Lipoprotein (HDL), which effectively neutralizes its biological potency. LBP was demonstrated to protect mice from septic shock caused by LPS or gram negative bacteria

Pathways: TLR Signalweg, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Positive Regulation of Immune Effector Process, Toll-Like Receptors Cascades, Monocarboxylic Acid Catabolic Process